{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:29:09Z","timestamp":1790872149054,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 DK092354"],"award-info":[{"award-number":["K23 DK092354"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03 DK104013"],"award-info":[{"award-number":["R03 DK104013"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL127028"],"award-info":[{"award-number":["R01 HL127028"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL107577"],"award-info":[{"award-number":["R01 HL107577"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11897-016-0290-z","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T08:47:24Z","timestamp":1461746844000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?"],"prefix":"10.1007","volume":"13","author":[{"given":"Ruth F.","family":"Dubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"290_CR1","unstructured":"Cardiovascular disease in patients with CKD, Vol.1 Ch. 4 [\n                    http:\/\/www.usrds.org\/2014\/view\/v1_04.aspx\n                    \n                  ]"},{"key":"290_CR2","unstructured":"Adult population of the United States [\n                    http:\/\/www.census.gov\n                    \n                  ]."},{"issue":"21","key":"290_CR3","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/eurheartj\/ehr190","volume":"32","author":"K Damman","year":"2011","unstructured":"Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705\u201312.","journal-title":"Eur Heart J"},{"issue":"1","key":"290_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51\u20138.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"290_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703\u201311.","journal-title":"Eur Heart J"},{"key":"290_CR6","unstructured":"Costs of chronic kidney disease [\n                    http:\/\/www.usrds.org\/2010\/view\/v1_09.asp\n                    \n                  ]"},{"issue":"9","key":"290_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","volume":"34","author":"T Yildirim","year":"2012","unstructured":"Yildirim T, Arici M, Piskinpasa S, Aybal-Kutlugun A, Yilmaz R, Altun B, et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3\u20135 in clinical practice: a safety concern? Ren Fail. 2012;34(9):1095\u20139.","journal-title":"Ren Fail"},{"issue":"10","key":"290_CR8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1681\/ASN.2012020145","volume":"23","author":"M Park","year":"2012","unstructured":"Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012;23(10):1725\u201334.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"290_CR9","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408.","journal-title":"J Clin Invest"},{"issue":"2","key":"290_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25(2):349\u201360.","journal-title":"J Am Soc Nephrol"},{"key":"290_CR11","doi-asserted-by":"crossref","unstructured":"Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal syndrome and the role of the bone-mineral axis and anemia. Am J Kidney Dis 2015.","DOI":"10.1053\/j.ajkd.2014.12.016"},{"issue":"1","key":"290_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.ajkd.2005.09.029","volume":"47","author":"MI Yilmaz","year":"2006","unstructured":"Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47(1):42\u201350.","journal-title":"Am J Kidney Dis"},{"key":"290_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-662-45805-1_12","volume":"218","author":"JP Stasch","year":"2013","unstructured":"Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279\u2013313.","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"290_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","volume":"18","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123\u201334.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"290_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1053\/j.ajkd.2012.07.029","volume":"61","author":"D Bolignano","year":"2013","unstructured":"Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61(4):612\u201322.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"290_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ki.2015.27","volume":"88","author":"D Bolignano","year":"2015","unstructured":"Bolignano D, Lennartz S, Leonardis D, D\u2019Arrigo G, Tripepi R, Emrich IE, et al. High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2\u20134 chronic kidney disease. Kidney Int. 2015;88(1):130\u20136.","journal-title":"Kidney Int"},{"issue":"2","key":"290_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000350952","volume":"3","author":"L Di Lullo","year":"2013","unstructured":"Di Lullo L, Floccari F, Rivera R, Barbera V, Granata A, Otranto G, et al. Pulmonary hypertension and right heart failure in chronic kidney disease: new challenge for 21st-century cardionephrologists. Cardiorenal Med. 2013;3(2):96\u2013103.","journal-title":"Cardiorenal Med"},{"key":"290_CR18","unstructured":"Group. KDIGOKBPW: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012(2):337\u2013414."},{"issue":"3","key":"290_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"290_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","volume":"63","author":"Y Matsumoto","year":"2014","unstructured":"Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63(6):528\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"290_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","volume":"70","author":"F Zannad","year":"2006","unstructured":"Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318\u201324.","journal-title":"Kidney Int"},{"issue":"21","key":"290_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","volume":"56","author":"G Cice","year":"2010","unstructured":"Cice G, Di Benedetto A, D\u2019Isa S, D\u2019Andrea A, Marcelli D, Gatti E, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"290_CR23","unstructured":"Cardiovascular Disease Vol 2. Ch. 4 [\n                    http:\/\/www.usrds.org\/atlas.aspx\n                    \n                  ]"},{"issue":"14","key":"290_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"3","key":"290_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"290_CR26","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1161\/01.CIR.89.5.2070","volume":"89","author":"WJ Paulus","year":"1994","unstructured":"Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89(5):2070\u20138.","journal-title":"Circulation"},{"issue":"1","key":"290_CR27","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.01147.2003","volume":"287","author":"WJ Paulus","year":"2004","unstructured":"Paulus WJ, Bronzwaer JG. Nitric oxide\u2019s role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol. 2004;287(1):H8\u201313.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"290_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCRESAHA.108.184408","volume":"104","author":"M Kruger","year":"2009","unstructured":"Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104(1):87\u201394.","journal-title":"Circ Res"},{"issue":"9","key":"290_CR29","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1161\/01.CIR.91.9.2345","volume":"91","author":"AM Zeiher","year":"1995","unstructured":"Zeiher AM, Krause T, Schachinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995;91(9):2345\u201352.","journal-title":"Circulation"},{"issue":"2","key":"290_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1523-1755.2005.00429.x","volume":"68","author":"K Ito","year":"2005","unstructured":"Ito K, Chen J, Seshan SV, Khodadadian JJ, Gallagher R, El Chaar M, et al. Dietary arginine supplementation attenuates renal damage after relief of unilateral ureteral obstruction in rats. Kidney Int. 2005;68(2):515\u201328.","journal-title":"Kidney Int"},{"issue":"14","key":"290_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/092986708784567725","volume":"15","author":"Y Wang-Rosenke","year":"2008","unstructured":"Wang-Rosenke Y, Neumayer HH, Peters H. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr Med Chem. 2008;15(14):1396\u2013406.","journal-title":"Curr Med Chem"},{"key":"290_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","volume":"21","author":"JP Stasch","year":"2015","unstructured":"Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol. 2015;21:95\u2013104.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"290_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bjp.0706792","volume":"148","author":"P Kalk","year":"2006","unstructured":"Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, et al. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy. Br J Pharmacol. 2006;148(6):853\u20139.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"290_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1523-1755.2005.00380.x","volume":"68","author":"Y Wang","year":"2005","unstructured":"Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, et al. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int. 2005;68(1):47\u201361.","journal-title":"Kidney Int"},{"issue":"7","key":"290_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021853","volume":"6","author":"S Geschka","year":"2011","unstructured":"Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One. 2011;6(7), e21853.","journal-title":"PLoS One"},{"issue":"8","key":"290_CR36","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","volume":"28","author":"Y Sharkovska","year":"2010","unstructured":"Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28(8):1666\u201375.","journal-title":"J Hypertens"},{"issue":"Suppl 12","key":"290_CR37","first-page":"S39","volume":"20","author":"C Zoccali","year":"2007","unstructured":"Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20 Suppl 12:S39\u201344.","journal-title":"J Nephrol"},{"key":"290_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","volume":"191","author":"JP Stasch","year":"2009","unstructured":"Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;191:277\u2013308.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"290_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"key":"290_CR40","doi-asserted-by":"crossref","unstructured":"Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F et al.. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015.","DOI":"10.1183\/09031936.00090614"},{"issue":"4","key":"290_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"290_CR42","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1183\/09031936.00087114","volume":"45","author":"G Simonneau","year":"2015","unstructured":"Simonneau G, D\u2019Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293\u2013302.","journal-title":"Eur Respir J"},{"issue":"5","key":"290_CR43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.14-0106","volume":"146","author":"D Bonderman","year":"2014","unstructured":"Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5):1274\u201385.","journal-title":"Chest"},{"issue":"5","key":"290_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502\u201311.","journal-title":"Circulation"},{"issue":"9","key":"290_CR45","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.135","volume":"16","author":"B Pieske","year":"2014","unstructured":"Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16(9):1026\u201338.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"290_CR46","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314(21):2251\u201362.","journal-title":"JAMA"},{"issue":"25","key":"290_CR47","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1161\/CIRCULATIONAHA.111.048520","volume":"124","author":"K Bishu","year":"2011","unstructured":"Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124(25):2882\u201391.","journal-title":"Circulation"},{"issue":"5","key":"290_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","volume":"132","author":"AM Shah","year":"2015","unstructured":"Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132(5):402\u201314.","journal-title":"Circulation"},{"issue":"10","key":"290_CR49","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1681\/ASN.2013070734","volume":"25","author":"R Kramann","year":"2014","unstructured":"Kramann R, Erpenbeck J, Schneider RK, Rohl AB, Hein M, Brandenburg VM, et al. Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol. 2014;25(10):2351\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"290_CR50","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2215\/CJN.10671012","volume":"8","author":"YW Liu","year":"2013","unstructured":"Liu YW, Su CT, Sung JM, Wang SP, Su YR, Yang CS, et al. Association of left ventricular longitudinal strain with mortality among stable hemodialysis patients with preserved left ventricular ejection fraction. Clin J Am Soc Nephrol. 2013;8(9):1564\u201374.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"290_CR51","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/hy0302.104674","volume":"39","author":"SG Myerson","year":"2002","unstructured":"Myerson SG, BelIenger NG, Pennell OJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension. 2002;39(3):750\u20135.","journal-title":"Hypertension"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-016-0290-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-016-0290-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-016-0290-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-016-0290-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:45:09Z","timestamp":1589737509000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-016-0290-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1007\/s11897-016-0290-z","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]},"assertion":[{"value":"27 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ruth F. Dubin declares that they have no conflict of interest.Sanjiv J. Shah has received consulting fees from AstraZeneca, Bayer, Merck, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}